非他汀类降脂药的临床应用评价.pptxVIP

非他汀降脂药物临床应用评价;非他汀降脂药物;烟 酸;烟酸降低TG作用强;烟酸升高HDL-C明显;烟酸中度降低TC和LDL-C;ATP III 对烟酸的评价（一）;ATP III对烟酸评价（二）;为什么烟酸在临床应用不广泛？;烟酸（Niacin) ;NIASPAN?（诺之平） Pooled Efficacy Data From Two Placebo-Controlled Studies;Percent Change From Baseline in HDL-C:Dose-Escalation Study;HATS: Percent Change in Stenosis;辛伐他汀与烟酸合用的安全性与耐受性;ARBITER-2;ARBITER-2;ARBITER-2;安慰剂与ER烟酸组治疗前后CIMT变化比较;结论;贝特类(又称苯氧芳酸类）;贝特类调脂作用机制（一）;贝特类调脂作用机制（二）;贝特类调脂作用机制（三）;纤维芳酸类（贝特类）;纤维芳酸类;贝特类调脂药适应证（一）;贝特类调脂药适应证（二）;贝特类调脂药适应证（三）;The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Trial;;Lipid Effects of Fenofibrate After 4 Months;